Immunology & Inflammation

A three-component research blend combining GHK-Cu 50 mg, BPC-157 10 mg and KPV 10 mg in a single lyophilized vial (70 mg total). The three components address distinct but complementary layers of tissue repair: GHK-Cu modulates the expression of thousands of genes involved in ECM remodelling, collagen and elastin synthesis, angiogenesis and scarless healing; BPC-157 supports VEGF-driven angiogenesis, fibroblast migration and collagen production at the repair site; and KPV suppresses the NF-κB inflammatory pathway that would otherwise antagonise the ECM and vascular repair activities of the other two components. At the reference reconstitution (5 mL bacteriostatic water → 10 mg/mL GHK-Cu + 2 mg/mL BPC-157 + 2 mg/mL KPV) and 0.2 mL injection volume, all three components fall within their individually-established therapeutic ranges — a distinguishing feature of Aura relative to other multi-component repair blends. No blend-specific FDA authorisation exists; the individual components have their own regulatory profiles (see the component compound pages).

A four-component research blend that combines all three peptide families addressed by the other repair blends plus the anti-inflammatory KPV component. Composition: GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg + KPV 10 mg = 80 mg total. The mechanism story covers all four rate-limiting layers of tissue repair: GHK-Cu at the gene-level ECM signalling layer, TB-500 at the cellular migration and cytoskeletal remodelling layer, BPC-157 at the vascular supply and fibroblast layer, and KPV at the inflammatory-environment control layer. In effect, Klow is Glow plus KPV — adding NF-κB pathway suppression to the three mechanistic components of Glow — and Aura plus TB-500 — adding cellular migration to the three components of Aura. It is the most comprehensive of the repair blends when all four components are available and the intended use warrants their combined effect.

A three-amino-acid peptide (Lys-Pro-Val) that constitutes the C-terminal fragment of α-melanocyte-stimulating hormone. KPV retains α-MSH's anti-inflammatory activity while losing its pigmentation, appetite, and sexual-arousal activities — the pharmacological signature of the melanocortin receptors that the parent hormone binds. The scientifically interesting fact is that KPV's anti-inflammatory effect appears to be MC-receptor-independent: it enters cells via the PepT1 oligopeptide transporter and modulates NF-κB signalling intracellularly. Research-only; no approved indication in any jurisdiction.

A 28-amino-acid N-acetylated peptide originally isolated by Allan Goldstein and colleagues from bovine thymus in 1972 as part of 'fraction 5'. It is a naturally occurring proteolytic product of prothymosin alpha in humans. Thymosin alpha-1 modulates both innate and adaptive immunity, principally by signalling through Toll-like receptors 2 and 9 on dendritic cells, enhancing dendritic cell maturation, promoting Th1-polarised T-cell responses, and increasing natural killer cell activity. It is approved as thymalfasin (Zadaxin, SciClone Pharmaceuticals) in more than 35 countries — including China, Argentina, Brazil, Italy, Mexico, Philippines and Singapore — for chronic hepatitis B, adjunctive treatment of chronic hepatitis C, and various immune-restoration indications. It has never been FDA-approved in the United States or EMA-authorised in the European Union.